Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action
- 43 Downloads
The pharmacological activity of Acacia nilotica’s phytochemical constituents was confirmed with evidence-based studies, but the determination of exact targets that they bind and the mechanism of action were not done; consequently, we aim to identify the exact targets that are responsible for the pharmacological activity via the computational methods. Furthermore, we aim to predict the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates. To achieve those goals, various computational methods were used including the ligand-based virtual screening and molecular docking. Moreover, pkCSM and SwissADME web servers were used for the prediction of pharmacokinetics and safety. The total number of the investigated compounds and targets was 25 and 61, respectively. According to the results, the pharmacological activity was attributed to the interaction with essential targets. Ellagic acid, Kaempferol, and Quercetin were the best A. nilotica’s phytochemical constituents that contribute to the therapeutic activities, were non-toxic as well as non-carcinogen. The administration of Ellagic acid, Kaempferol, and Quercetin as combined drug via the novel drug delivery systems will be a valuable therapeutic choice for the treatment of recent diseases attacking the public health including cancer, multidrug-resistant bacterial infections, diabetes mellitus, and chronic inflammatory systemic disease.
KeywordsA. nilotica Ellagic acid Kaempferol Quercetin Multiple mechanisms of action ADMET and computer-aided drug discovery
Compliance with Ethical Standards
Conflict of Interest
The authors declare that having no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subject performed by any of the authors
- 1.Islam SU, Rather LJ, Mohammad F. Acacia nilotica (L.): A review of its traditional uses, phytochemistry, and pharmacology. Sustain Chem Pharm. 2015;8:2352–5541.Google Scholar
- 2.Shakya AK. Medicinal plants: future source of new drugs. Int J Herbal Med. 2016;4:59–64.Google Scholar
- 4.N. C. Institute. Cancer statistics. www.cancer.gov. Accessed April 2018.
- 6.A. D. Association. Statistics about diabetes. www.diabetes.org, Accessed March 2018.
- 7.Straub RH, Schradin C. Chronic inflammatory systemic diseases an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol Med Public Health. 2016;2016:73–51.Google Scholar
- 8.Eweas AF, Maghrabi IA, Namarneh AI. Advances in molecular modeling and docking as a tool for modern drug discovery. Sch Res Lib Der Pharma Chem. 2014;6:211–28.Google Scholar
- 9.Saher Afshan Shaikh TJ. Sandhu G, Soni A, Jayaram B. From drug target to leads-sketching a physico-chemical pathway for lead molecule design in silico. Front Med Chem. 2011;6.Google Scholar
- 15.Wadhwa B, Mahajan P, Barik MR, Malik F, Nargotra A. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1. Mol Divers. 2019.Google Scholar
- 16.Pereira F, Aires-de-Sousa J. Computational methodologies in the exploration of the marine natural product leads. Mar Drugs. 2018;16.Google Scholar
- 22.Noel MB, Boyle MO’, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3.Google Scholar
- 26.T. N. Consortium. The Universal Protein Resource (UniProt). Nucleic Acids Res. 2008;36.Google Scholar
- 28.Li YH, Yu YY, Li XX, Zhang P, Tang J, Yang QX, et al. Therapeutic target database update 2018: enrich resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 2018;46:D1121–7.Google Scholar
- 34.Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anticancer Drug Des. 1987;2:151–64.Google Scholar
- 39.Moretti RM, Montagnani Marelli M, Motta M, Limonata P. Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer. Oncol Rep. 2002;9:1139–43.Google Scholar
- 47.Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveniand H, Ben-Sasson SA. Lyn is a target gene for prostate cancer sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 2004.Google Scholar
- 64.Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, Burks RF. Antidiarrheal properties of supraspinal mu and delta and kappa opioid receptors: inhibition of diarrhea without constipation. J Pharmacol Exp Ther. 1989;249:83–90.Google Scholar
- 71.Rowlett VW, VKPS M, Karlstaedt A, Dowhan W, Taegtmeyer H, Margolin W, et al. Impact of membrane phospholipid alterations in Escherichia coli on cellular function and bacterial stress adaptation. J Bacteriol. 2017.Google Scholar
- 77.Ibrahim MM, Elsaman T, Al-Nour MY. Synthesis, anti-inflammatory activity, and in silico study of novel diclofenac and isatin conjugates. Int J Med Chem. 2018;2018:9139786.Google Scholar
- 80.Hassan M, Sallam H, Hassan Z. The role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor-roscovitine. Sultan Qaboos Univ Med J. 2011;11:165–78.Google Scholar
- 85.Kasikci MB, Bagdatlioglu N. Bioavailability of quercetin. Curr Res in Nutr Food Sci. 2016;4.Google Scholar
- 89.Chen ZP, Sun J, Chen HX, Xiao YY, et al. Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol, and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats. Fitoterapia. 2010;81:1045–52.CrossRefGoogle Scholar
- 91.Neves BJ, Braga RC, Melo-Filho CC, Teofilo J, Moreira-Filho JT, Muratov EN, et al. QSAR-based virtual screening: advances and applications in drug discovery. Front Pharmacol. 2018.Google Scholar